ATR and ovarian carcinoma: The DUETTE trial (ClinicalTrials.gov Identifier: NCT04239014) is assessing the combination of ceralasertib (ATR inhibitor) and Olaparib in platinum-sensitive ovarian cancer previously treated with PARPi.